Clinical Trial Detail

NCT ID NCT04302025
Title A Study of Alectinib, Entrectinib, or Vemurafenib Plus Cobimetinib in Participants With Stages I-III Non-Small Cell Lung Cancer With ALK, ROS1, NTRK, or BRAF v600E Molecular Alterations
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Genentech, Inc.
Indications

lung non-small cell carcinoma

Therapies

Cobimetinib + Vemurafenib

Entrectinib

Alectinib

Age Groups: adult senior

Additional content available in CKB BOOST